Exhibit (a)(ii) DEPOSIT AGREEMENT by and amongDeposit Agreement • September 4th, 2025 • Citibank,N.A./ADR • Services-medical laboratories • New York
DEPOSIT AGREEMENT, dated as of July 21, 2020, by and among (i) Renalytix AI plc, a public limited company incorporated under the laws of England and Wales, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
Exhibit (a)(i) RENALYTIX plc AND CITIBANK, N.A., As Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED AND OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF JULY 21, 2020 Amendment No. 1 to Deposit...Deposit Agreement • September 4th, 2025 • Citibank,N.A./ADR • Services-medical laboratories • New York
AMENDMENT NO. 1 TO DEPOSIT AGREEMENT, dated as of [●], 2025 (the “Amendment”), by and among Renalytix plc, a public limited company incorporated under the laws of England and Wales (the “Company”), Citibank, N.A., a national banking association organized under the laws of the United States of America (the “Depositary”), and all Holders and Beneficial Owners (each as defined in the Deposit Agreement (as hereinafter defined)) from time to time of American Depositary Shares (“ADSs”).